Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
复制标题
重组 E 型和 B 亚型人类免疫缺陷病毒 1 型包膜糖蛋白 120 疫苗组合在健康泰国成年人中的安全性和免疫原性。
DOI：
--
复制
发表时间：
2003
影响因子：
6.4
通讯作者：
A. Brown
中科院分区：
文献类型：
--
作者：
P. Pitisuttithum;S. Nitayaphan;P. Thongcharoen;C. Khamboonruang;Jerome H. Kim;M. de Souza;T. Chuenchitra;R. Garner;D. Thapinta;V. Polonis;S. Ratto;P. Chanbancherd;J. Chiu;D. Birx;A. Duliege;J. McNeil;A. Brown
Safety and immunogenicity of 2 recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein (gp) 120 vaccines derived from SF2 (subtype B) and CM235 (CRF01_AE, Thai E) were evaluated in 370 Thai adults at low risk of HIV infection. Various doses of CM235 (25, 50, or 100 microg) and SF2 (0, 25, or 50 microg) gp120 were used. Eighty volunteers received placebo. There were no serious adverse events related to vaccination. Binding antibody developed in all vaccine recipients. There was no dose response to CM235 gp120, but a dose response to gp120 SF2 was present. Neutralizing antibodies to subtype E HIV-1 NPO3 and subtype B HIV-1 SF2 developed in 84% and 82% of vaccine recipients, respectively. Lymphoproliferative responses were detected in >95% of vaccine recipients. There was no evidence of antigenic interference in HIV-specific humoral or cellular responses. The gp120 Thai E and SF2 vaccines were safe and immunogenic in combination and could be advanced into phase 3 testing.
候选艾滋病疫苗。
DOI：
10.1056/nejm199511163332007
发表时间：
1995
期刊：
The New England journal of medicine
影响因子：
--
作者：
Graham,BS;Wright,PF
通讯作者：
Wright,PF
通过剂量和给药时间表调节 HIV-1MN 重组 gp160 疫苗的免疫反应。
影响因子：
5.5
作者：
Gorse,GJ;McElrath,MJ;Matthews,TJ;Hsieh,RH;Belshe,RB;Corey,L;Frey,SE;Kennedy,DJ;Walker,MC;Eibl,MM
通讯作者：
Eibl,MM
影响因子：
1.5
作者：
Gorse, GJ;Corey, L;Belshe, RB
通讯作者：
Belshe, RB